Boule Diagnostics Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Boule Diagnostics ha aumentado sus beneficios a una tasa media anual de 5.4%, mientras que los beneficios de la industria de Medical Equipment han experimentado un crecimiento de 6.3% anual. Los ingresos han ido creciendo a una tasa media de 5.7% al año. La rentabilidad financiera de Boule Diagnostics es de 5.4%, y sus márgenes netos son de 4.7%.

Información clave

5.4%

Tasa de crecimiento de los beneficios

-5.9%

Tasa de crecimiento del BPA

Crecimiento de la industria Medical Equipment	6.2%
Tasa de crecimiento de los ingresos	5.7%
Rentabilidad financiera	5.4%
Margen neto	4.7%
Próxima actualización de resultados	22 Jul 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Results: Boule Diagnostics AB (publ) Exceeded Expectations And The Consensus Has Updated Its Estimates

May 10

Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 47% Below Their Intrinsic Value Estimate

Mar 20

Here's What Analysts Are Forecasting For Boule Diagnostics AB (publ) (STO:BOUL) After Its Yearly Results

Feb 09

Boule Diagnostics AB (publ) (STO:BOUL) Screens Well But There Might Be A Catch

Dec 30

Investors Could Be Concerned With Boule Diagnostics' (STO:BOUL) Returns On Capital

Jul 25

Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 49% Below Their Intrinsic Value Estimate

May 26

Investors Could Be Concerned With Boule Diagnostics' (STO:BOUL) Returns On Capital

Feb 03

The Returns At Boule Diagnostics (STO:BOUL) Aren't Growing

Apr 29

Should You Investigate Boule Diagnostics AB (publ) (STO:BOUL) At kr67.70?

Apr 09

Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 27% Below Their Intrinsic Value Estimate

Mar 25

Consider This Before Buying Boule Diagnostics AB (publ) (STO:BOUL) For The 1.0% Dividend

Mar 07

Is Boule Diagnostics' (STO:BOUL) 210% Share Price Increase Well Justified?

Feb 17

These 4 Measures Indicate That Boule Diagnostics (STO:BOUL) Is Using Debt Extensively

Jan 30

Is Boule Diagnostics AB (publ)'s (STO:BOUL) Shareholder Ownership Skewed Towards Insiders?

Jan 14

How Many Boule Diagnostics AB (publ) (STO:BOUL) Shares Did Insiders Buy, In The Last Year?

Dec 28

Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 47% Below Their Intrinsic Value Estimate

Dec 10

What Do The Returns On Capital At Boule Diagnostics (STO:BOUL) Tell Us?

Nov 22

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Boule Diagnostics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

OM:BOUL Ingresos, gastos y beneficios (SEK Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Mar 24	576	27	158	48
31 Dec 23	571	25	153	53
30 Sep 23	572	19	149	52
30 Jun 23	558	17	148	50
31 Mar 23	559	16	146	53
31 Dec 22	548	13	144	52
30 Sep 22	539	27	138	50
30 Jun 22	525	32	131	48
31 Mar 22	495	28	126	45
31 Dec 21	463	23	120	43
30 Sep 21	416	-27	115	42
30 Jun 21	403	-13	113	42
31 Mar 21	383	-55	107	44
31 Dec 20	400	-48	111	43
30 Sep 20	437	-8	116	41
30 Jun 20	470	-8	119	37
31 Mar 20	499	35	130	32
31 Dec 19	499	38	128	30
30 Sep 19	476	32	126	31
30 Jun 19	456	21	124	33
31 Mar 19	444	36	115	33
31 Dec 18	424	41	110	29
30 Sep 18	425	48	111	24
30 Jun 18	424	60	112	25
31 Mar 18	421	43	111	27
31 Dec 17	428	37	116	32
30 Sep 17	422	31	114	38
30 Jun 17	421	28	110	38
31 Mar 17	419	38	109	38
31 Dec 16	397	36	105	37
30 Sep 16	383	36	97	40
30 Jun 16	364	22	96	42
31 Mar 16	341	15	93	42
31 Dec 15	331	15	89	40
30 Sep 15	333	29	95	31
30 Jun 15	318	33	91	26
31 Mar 15	309	33	89	23
31 Dec 14	307	30	88	24
30 Sep 14	289	14	83	24
30 Jun 14	285	-68	83	25
31 Mar 14	287	-64	84	24
31 Dec 13	277	-70	84	24
30 Sep 13	281	-65	85	25
30 Jun 13	275	8	86	24

Ingresos de calidad: BOUL tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio (4.4%) de BOUL son superiores a los del año pasado (2.3%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de BOUL han crecido un 5.4% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de BOUL en el último año (96.2%) supera su media de 5 años (-3.9% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de BOUL en el último año (96.2%) superó al de la industria Medical Equipment 25.4%.

Boule Diagnostics Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Información clave

Actualizaciones de resultados anteriores recientes

First quarter 2024 earnings: EPS exceeds analyst expectations

Full year 2023 earnings: EPS exceeds analyst expectations

Boule Diagnostics AB (publ) to Report Fiscal Year 2023 Final Results on Apr 16, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Boule Diagnostics AB (publ) to Report Q2, 2024 Results on Jul 22, 2024

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Recent updates

Results: Boule Diagnostics AB (publ) Exceeded Expectations And The Consensus Has Updated Its Estimates

Boule Diagnostics AB (Publ) Appoints Rikke Rytter as Director

First quarter 2024 earnings: EPS exceeds analyst expectations

Full year 2023 earnings: EPS exceeds analyst expectations

Price target decreased by 13% to kr10.40

Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 47% Below Their Intrinsic Value Estimate

Boule Diagnostics AB (publ) to Report Fiscal Year 2023 Final Results on Apr 16, 2024

Here's What Analysts Are Forecasting For Boule Diagnostics AB (publ) (STO:BOUL) After Its Yearly Results

Full year 2023 earnings: EPS exceeds analyst expectations

Boule Diagnostics AB (publ) to Report Q2, 2024 Results on Jul 22, 2024

Boule Diagnostics AB (publ) (STO:BOUL) Screens Well But There Might Be A Catch

Investors Could Be Concerned With Boule Diagnostics' (STO:BOUL) Returns On Capital

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 31% to kr12.50

Boule Diagnostics AB (publ) to Report Q1, 2024 Results on May 07, 2024

Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 49% Below Their Intrinsic Value Estimate

Independent Director recently bought kr54k worth of stock

Consensus EPS estimates increase by 10%

Independent Director recently bought kr120k worth of stock

Price target decreased by 10.0% to kr18.00

Independent Director recently bought kr60k worth of stock

Independent Chairman of the Board recently bought kr100k worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 26%, revenue upgraded

Boule Diagnostics AB (publ) to Report Q3, 2023 Results on Nov 09, 2023

Boule Diagnostics AB (publ) to Report Q3, 2023 Results on Sep 09, 2023

President recently bought kr974k worth of stock

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Consensus EPS estimates fall by 28%

Consensus forecasts updated

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Boule Diagnostics' (STO:BOUL) Solid Profits Have Weak Fundamentals

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Returns On Capital Signal Tricky Times Ahead For Boule Diagnostics (STO:BOUL)

Investor sentiment deteriorated over the past week

Boule Diagnostics AB (publ), Annual General Meeting, May 04, 2023

Boule Diagnostics AB (publ) to Report Q1, 2023 Results on May 03, 2023

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Upcoming dividend of kr0.55 per share

Price target decreased to kr60.00

Full year 2021 earnings: EPS and revenues exceed analyst expectations

We Think Boule Diagnostics (STO:BOUL) Can Stay On Top Of Its Debt

Consensus EPS estimates fall by 13%

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Investors Could Be Concerned With Boule Diagnostics' (STO:BOUL) Returns On Capital

Third quarter 2021 earnings released: EPS kr0.37 (vs kr1.04 in 3Q 2020)

President recently bought kr119k worth of stock

Second quarter 2021 earnings released: kr0.07 loss per share (vs kr2.21 loss in 2Q 2020)

Price target decreased to kr70.00

First quarter 2021 earnings released

Price target increased to kr80.00

Upcoming dividend of kr0.55 per share

The Returns At Boule Diagnostics (STO:BOUL) Aren't Growing

Full year 2020 earnings released: kr2.47 loss per share (vs kr1.93 profit in FY 2019)

Should You Investigate Boule Diagnostics AB (publ) (STO:BOUL) At kr67.70?

Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 27% Below Their Intrinsic Value Estimate

Consider This Before Buying Boule Diagnostics AB (publ) (STO:BOUL) For The 1.0% Dividend

Is Boule Diagnostics' (STO:BOUL) 210% Share Price Increase Well Justified?

Independent Chairman of the Board recently bought kr438k worth of stock

Full year 2020 earnings released: kr2.47 loss per share (vs kr1.93 profit in FY 2019)

Earnings beat expectations, revenue disappoints

Price target lowered to kr66.00

Boule Diagnostics AB (publ) to Report Fiscal Year 2020 Results on Feb 03, 2021

These 4 Measures Indicate That Boule Diagnostics (STO:BOUL) Is Using Debt Extensively

Is Boule Diagnostics AB (publ)'s (STO:BOUL) Shareholder Ownership Skewed Towards Insiders?

Desglose de ingresos y gastos
Beta